Compare MDRR & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MDRR | NEUP |
|---|---|---|
| Founded | 2015 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.3M | 20.6M |
| IPO Year | 2015 | 2002 |
| Metric | MDRR | NEUP |
|---|---|---|
| Price | $12.20 | $3.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $21.00 |
| AVG Volume (30 Days) | 14.4K | ★ 47.1K |
| Earning Date | 03-02-2026 | 05-23-2026 |
| Dividend Yield | ★ 2.43% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.74 | N/A |
| Revenue | $10,396,618.00 | ★ $15,649,448.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.57 | ★ N/A |
| Revenue Growth | ★ 6.79 | N/A |
| 52 Week Low | $9.47 | $3.19 |
| 52 Week High | $14.52 | $21.31 |
| Indicator | MDRR | NEUP |
|---|---|---|
| Relative Strength Index (RSI) | 56.59 | 45.28 |
| Support Level | $12.17 | $3.75 |
| Resistance Level | $14.04 | $4.15 |
| Average True Range (ATR) | 0.23 | 0.15 |
| MACD | 0.06 | -0.01 |
| Stochastic Oscillator | 68.70 | 9.52 |
Medalist Diversified Inc owns ten investment properties comprised of three retail properties, three flex/industrial properties, and four STNL properties, including the Tesla Pensacola Property. Through its subsidiary, the company sponsors Delaware Statutory Trusts (DSTs) that provide accredited investors access to institutional-quality real estate with the transparency and governance of a public company. The company has three reportable segments, consisting of retail center properties, flex center properties, and STNL properties. The company generates the majority of its revenue from the Retail Center Property.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.